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INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune disease
characterized by chronic joint inflammation, which, if
left untreated, may lead to bony erosions, deformity, joint
destruction and disability. The therapies currently used to
treat RA include non-steroidal anti-inflammatory drugs to
manage pain and inflammation, disease-modifying anti-
rheumatic drugs (DMARDs) as a “first-line” therapy for
newly diagnosed cases of RA, and biological-response
modifiers, which are selective agents that specifically
inhibit targeted molecules of the immune system.
Glucocorticoids and other anti-rheumatic drugs are also
used to treat RA. DMARDs include sulfasalazine,
hydroxychloroquine, sulfasalazine, leflunomide, and
methotrexate. Although DMARDs are effective, the goal of
therapy should be remission (achieved in only 30 to 40%);
therefore, development of new therapies is still needed.
Researchers are making a concerted effort to develop
new immunomodulatory agents, specifically biological
agents, which block the pro-inflammatory cytokines present
in RA. These biological-response modifiers include inhibitors
of tumor necrosis factor-alpha (TNF-α) (adalimumab,
etanercept, and infliximab) [1,2], a recombinant inhibitor
of interleukin (IL)-1 (anakinra) [3], a chimeric anti-CD20
monoclonal antibody (rituximab) [4], and a costimulation
blocker (abatacept). Additional therapies for RA under
current investigation include new TNF-α inhibitors, anti-
IL-6-receptor monoclonal antibodies, and antibodies
targeting proteins involved in B-cell function and survival.
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REVIEW
English articles on abatacept, golimumab, and tocilizumab in rheumatoid arthritis published between 2002 and
2009 were reviewed systematically. All randomized clinical trials, open-label extensions, meta-analyses, and
reviews were examined. There were thirteen articles on abatacept, four on golimumab, and seven on
tocilizumab. All three drugs were effective in methotrexate-naïve, methotrexate-incomplete responders, and
tumor-necrosis-factor-failure rheumatoid arthritis patients. Of the three, only abatacept has been tested in a
head-to-head trial with infliximab, in which it was found to be equivalent to infliximab. Golimumab resulted in a
more modest improvement than the others in methotrexate-naïve patients, although no direct comparisons
among the three drugs were possible or appropriate. Descriptive analysis of adverse events showed that patients
receiving abatacept, golimumab, and tocilizumab were subject to more adverse events than controls overall, as
expected. In the abatacept studies, a few cases of tuberculosis, more cardiovascular events and gastrointestinal
bleedings and more basal cell carcinoma were seen. Golimumab was associated with more skin rashes and
pneumonia, while tocilizumab was associated with increased lipids, more liver-function abnormalities, and
neutropenia. These new medications are useful additions to the rheumatologic armamentarium and represent
greater convenience (golimumab) or different mechanisms of action (abatacept and tocilizumab) than tumor-
necrosis-factor inhibitors for treating rheumatoid arthritis. As expected, some adverse events occur when using
these drugs and patients need to be watched carefully. (Korean J Intern Med 2010;25:1-17)
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Table 1. Study characteristics of abatacept
Author Design N-Aba / N-Ctrl Study Age, mean,  Disease RF, % CS, % Erosions DAS28 ESR, HAQ-DI
duration yr duration mm/hr
Westhovens et al. [8] R, DB,  256 / 253 1 yr 49.9  6.45 mon 96.4 50.1 6.25 (CRP) 1.7
placebo-
controlled
Kremer et al. [9] R, DB,  220 / 119 6 mon 55  9.4 yr 93 64.9 100% 5.5
placebo-
controlled
Kremer et al. [10] R, DB, 220 / 119 12 mon 55 9.4 yr 93 64.9 100% 5.5
placebo-
controlled 
Kremer et al. [11] R, DB, 433 / 219 12 mon 51.1 8.6 yr 80.7 70.9 Score 1.7
placebo- = 16.6
controlled 
Genant et al. [12] OLE of R, DB, 433 / 219 2 yr 51.1 8.6 yr 80.7 70.9 Score  1.7
placebo- = 16.6
controlled 
Kremer et al. [13] OLE of R, DB,  378 / 161 2 yr 50.8 8.5 yr 82 Score  6.4 (CRP) 1.7
placebo- = 25.1
controlled 
Schiff et al. [14] R, DB,  156 / 275 12 mon 49.1  7.8 yr 83.8 72.6 6.8 (ESR) 48.2 1.8
placebo-
controlled
Westhovens et al. [15] OLE of R, DB, 220 / 119 5 yr 55 9.4 yr 93 64.9 100% 5.5
placebo-
controlled 
Emery et al. [16] R, DB,  115 / 119 12 mon 55.2  9.3 yr
placebo-
controlled
Moreland et al. [17] R, DB,  90 / 32 85 day 48.3 3.5 yr 92.7 33
placebo-
controlled 
Genovese et al. [18] R, DB, 258 / 133 6 mon 53.2  11.9 yr 73.2 68.3 6.5
placebo-
controlled
Schiff et al. [19] Open- 449 / 597, 6 mon 54.4  11.6 yr 61.3 58.4 6.2 (CRP) 1.7
label trial washout/direct-
switch
Westhovens et al. [20] R, DB, 258 / 133 6 mon 53.2 11.9 yr 73.2 6.5 1.8
placebo-
controlled 
N-Aba, number-abatacept; N-Ctrl, number-control; RF, rheumatoid factor; CS, corticosteroid; DAS28, 28 joint disease activity score;
ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; R, random; DB, double-blind; CRP,
C-reactive protein; OLE, open label extension.Storage SS, et al. Three new biologics in the treatment of rheumatoid arthritis    3
We have chosen to examine three new biologics that
have shown promise and play important roles in the
treatment of RA. These new biologics include abatacept,
golimumab, and tocilizumab. Abatacept, which is
currently Food and Drug Administration (FDA) approved
for RA treatment, functions by selectively modulating the
CD80/CD86:CD28 co-stimulatory signal required for
complete T-cell activation [5]. Golimumab, a full human
anti-TNF-α monoclonal antibody, is also approved for the
treatment of RA [6]. Finally, tocilizumab, the first anti-IL-
6-receptor monoclonal antibody, has completed phase III
clinical trials for RA and is awaiting FDA approval [7].
Abatacept, golimumab, and tocilizumab may be beneficial
for treating RA in patients who do not respond to methotrex-
ate or other disease-modifying anti-rheumatic drugs.
METHODS
The evidence for the efficacy and safety of abatacept,
golimumab, and tocilizumab in the treatment of RA
patients has been reviewed systematically. In this review,
we focus primarily on a 28 joint disease activity score
(DAS28) remission and 20% response on the American
College of Rheumatology criteria (ACR20) as measures of
efficacy, though other measures are also examined. To
assess the tolerability of these new biologics, we include
information regarding discontinuation, adverse events,
serious adverse events, deaths, infections, cancers, acute
infusion reactions, and special interest items for each of
the three drugs. English language articles published from
2002 to July 2009 using PubMed were analyzed. Studies
were included if they were randomized-control or open-
label extension trials evaluating abatacept, golimumab, or
tocilizumab alone or in combination with DMARDs, as
compared with placebo or DMARDs alone. When available,
systematic reviews or meta-analyses from randomized
controlled trials were also included. Data were extracted
on the effects of abatacept, golimumab, and tocilizumab
on clinical outcomes. Results of this data extraction are
summarized in tables and then synthesized.
The percentages included in the adverse effect tables
(see Results section on safety) were derived from combining
information found in the text, tables, and graphs of their
respective cited articles. For some of the data found in the
adverse effect tables, we used figures taken from the listed
references to approximate the number and percentage of
patients experiencing particular adverse events. This was
especially important when evaluating lipid and liver
enzyme changes among patients receiving golimumab
Table 2. Study characteristics of golimumab
Author Design N-Gol / N-Ctrl Study  Age,  Disease RF, % CS, % DAS28 ESR, mm/hr HAQ-DI
duration, wk mean, yr duration, yr
Emery et al. [21] Multicentre, 477 / 160 52 49.5  3.55 66.70 5.1 (CRP),  ≥ 28, 1.5
R, DB, 6.3 (ESR) Westergren
placebo- method
controlled
Kay et al. [22] R, DB,  172 / 35 68 53 7.4 5.2 (CRP), ≥ 28, 1.55
placebo- 6.4 (ESR) Westergren
controlled, method
dose-ranging 
Keystone et al. [23] Multicentre, 311 / 133 24 51 5.8 83.60 69 4.87 (CRP), 1.34
R, DB, 6.04 (ESR)
placebo-
controlled
Smolen et al. [24] Multicentre, 306 / 155 24 55 9.4 72 6.3 30 1.6
R, DB,
placebo-
controlled
N-Gol, number-golimumab; N-Ctrl, number-control; RF, rheumatoid factor; CS, corticosteroid; DAS28, 28 joint disease activity score;
ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; R, random; DB, double-blind; CRP,
C-reactive protein.and tocilizumab. Additionally, if a reference table did not
list a particular adverse event, but the adverse event was
addressed within the text of the reference, we added it to
the total “n” for that particular adverse event subgroup
and then calculated the percentages shown. If there were
two different subgroups because different doses or routes
of administration were used, these were added together
and the percentages were calculated from the combined
group. Furthermore, if there were two time periods in a
drug study (e.g., an initial and crossover period), the
initial period was used. For some non-serious infections,
only the infections that were mentioned in the reference
text or tables were incorporated into adverse effect tables,
and a percentage was calculated from the total “n”. We
have categorized systemic disorders into life threatening
and non-serious disorders for some systems. In those
studies in which no such classification was available, we
only included combined percentages. Adverse effect tables
also group related laboratory abnormalities together into
single categories; for example, liver function tests include
transaminase and bilirubin values (this seemed reasonable
as changes in bilirubin were extremely rare). Similarly, for
lipid abnormalities, we included total cholesterol, low
density lipoprotein (LDL), and triglycerides, solely for
space reasons. “N/A” indicates that the data was not
available. “N” is the total number of patients in all studies,
and the percentages in parentheses represent the ranges
encountered in individual studies. 
RESULTS
Study characteristics
A total of 24 studies, four of which were open-label, met
our inclusion criteria and examined abatacept (n = 13) [8-
20], golimumab (n = 4) [21-24]  and tocilizumab (n = 7)
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Table 3. Study characteristics of tocilizumab
Author Design N-Toc / N- Study Age, Disease RF, % CS, % Erosions DAS28 ESR, mm/hr HAQ-DI
Ctrl duration, wk mean, yr duration, yr
Jones et al. [25] R, DB, 265 / 259 24 50.6 6.35 47.5 6.8 49.4 1.55
placebo-
controlled
Maini et al. [26] R, DB, 310 / 49 20 50.3 0.8 82.7 6.51 41
placebo-
controlled
Nishimoto et al. [27] Multicentre, 61 / 64 24 51.7 8.6 6.15 51.9
R, DB,
placebo-
controlled
Smolen et al. [28] R, DB, 418 / 204 24 50.9 7.56 77.4 55 6.8 50 1.6
placebo-
controlled
Nishimoto et al. [29] Multicentre, 157 / 145 52 53 2.3 Average 5.4  13.85 / 280 6.45 70.9
R, X-ray reader- mg/day
blinded, placebo-
controlled
Genovese et al. [30] Multicentre, 803 / 413 24 53.3 9.8 52.7 6.66 48.5 1.5
R, DB, placebo-
controlled
Emery et al. [31] R, DB, 331 / 158 24 52.8 11.7 75.7 55.9 6.79 51.6 1.7
placebo-
controlled
N-Toc, number-tocilizumab; N-Ctrl, number-control; RF, rheumatoid factor; CS, corticosteroid; DAS28, 28 joint disease activity score;
ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; R, random; DB, double-blind.Storage SS, et al. Three new biologics in the treatment of rheumatoid arthritis    5
Table 4. Efficacy of abatacept
ACR 20 Response DAS28 Remission
Author Design Type Abatacept, % Control, % Abatacept Control Abatacept, % Control, % Comments
Westhovens et al. [8] R, DB,  MTX naïve 57.4 42.3 - 3.22 - 2.49 41.40 23.30
placebo- (ACR 50) (ACR 50)
controlled
Kremer et al. [9] R, DB,  MTX failure 60 35.30
placebo-
controlled
Kremer et al. [10] R, DB, MTX failure 62.60 36.10 49.6% low 21.9% low 34.80 10.10
placebo- level of level of 
controlled disease disease
activity activity
(DAS28 ≤ 3.2) (DAS28 ≤ 3.2)
Kremer et al. [11] R, DB, MTX failure 73.10 39.70 42.5% low 9.9% low 23.80 1.90
placebo- level of  level of
controlled disease disease
activity activity
(DAS28 ≤ 3.2) (DAS28 ≤ 3.2)
Genant et al. [12] OLE of  MTX failure
R, DB,
placebo-
controlled
Kremer et al. [13] OLE of MTX failure 80.30 CRP, 30.9
R, DB, 
placebo-
controlled
There was significantly less
radiographic progression at
1 yr in the abatacept + MTX
group (mean change in TS =
0.63) compared to the placebo
group (mean change in TS =
1.06)
The results listed here
compare the CTLA4Ig 10
mg/kg + MTX group to the
placebo + MTX group.  Patients
in the CTLA4Ig 10 mg/kg +
MTX group had significant,
clinically meaningful improve-
ments in both summary scores
and all eight subscales of the
SF-36 compared to those in
the placebo + MTX group
The results listed here
compare the 10 mg/kg
abatacept + MTX to the
placebo + MTX group
At 12 mon, patients treated
with abatacept showed
statistically significant slowing
of structural damage compared
to patients in the placebo
group, as indicated by a 50%
reduction in change from
baseline in Genant-modified
Sharp scores compared to
placebo
From baseline to the end of
yr 2, the mean changes in
erosion score and joint space
narrowing score were less in
the abatacept group (0.84
and 0.71, respectively)
compared to the placebo/
abatacept group (1.69 and
1.48, respectively)
At 2 yr, 66.8% of patients in
the original abatacet group
showed a meaningful HAQ-
DI response for physical
function6 The Korean Journal of Internal Medicine Vol. 25, No. 1, March 2010
ACR 20 Response DAS28 Remission
Author Design Type Abatacept, % Control, % Abatacept Control Abatacept, % Control, % Comments
Schiff et al. [14] R, DB, MTX failure 72.40 55.80 - 2.88 - 2.25 18.70 12.20
placebo-
controlled
Westhovens et al. [15] OLE of MTX failure 82.70 CRP, 45.3
R, DB,
placebo-
controlled
Emery et al. [16] R, DB, MTX failure
placebo-
controlled
Moreland et al. [17] R, DB, At least 1 53 31
placebo- classic
controlled DMARD or
etanercept
failure
Genovese et al. [18] R, DB, TNF-α 50.40 19.50 17.1% low 3.1% low 10 0.80
placebo- failure level of level of
controlled disease disease
activity activity
(DAS28 ≤ 3.2) (DAS28 ≤ 3.2)
Schiff et al. [19] Open- TNF-α - 2 - 2 12 13.70
label trial failure
Westhovens et al. [20] R, DB, TNF-α
placebo- failure
controlled
ACR20, 20% response on the American College of Rheumatology criteria; DAS28, 28 joint disease activity score; R, random; DB,
double-blind; MTX, methotrexate; TS, total score; OLE, open label extension; CRP, C-reactive protein; HAQ-DI, Health Assessment
Questionnaire-Disability Index; TNF, tumor necrosis factor; SF-36, short form 36.
Note: For this study, the
“control group” refers to
patients in the infliximab
group
At yr 5, 52.8% of patients
had a meaningful mHAQ
response in physical
functioning
Remission rates in the
abatacept + MTX group were
greater at all time points
compared to remission rates
in the placebo + MTX group
The results listed here
compare the CTLA4Ig 10
mg/kg to the placebo group
At 6 mon, 47.3% of patients
in the abatacept group and
23.3% of patients in the
placebo group experienced
clinically meaningful improve-
ment in physical function as
defined by a reduction of at
least 0.3 from HAQ-DI baseline
For these results, the
"abatacept" group refers to
patients switched from an
anti-TNF agent to abatacept
following a washout period
(≥ 2 mon). The "control"
group refers to patients
switched directly from anti-
TNF therapy to abatacept
Patients in the treatment
group saw significant improv-
ements in QoL as assessed
by the HAQ and fatigue
indices, as well as on the SF-
36 physical and mental
summary scores and on seven
of the eight SF-36 scalesStorage SS, et al. Three new biologics in the treatment of rheumatoid arthritis    7
[25-31]. Within the abatacept studies, study durations
ranged from 85 days to 5 years, with disease durations
ranging from 6.45 months to 11.9 years (Table 1). The
golimumab studies ranged from 24 to 68 weeks in
duration, and participants in these trials had shorter
disease durations than those in the abatacept trials, with a
spread of 3.55 to 9.4 years (Table 2). Finally, the tocilizumab
study durations ranged from 20 to 52 weeks, with disease
durations ranging from 9.6 months to 11.7 years (Table 3).
The mean age ranges of the study participants was 48.3 to
55.2 years in the abatacept studies, 49.5 to 55 years in the
golimumab studies, and 50.3 to 53.3 years in the
tocilizumab studies. Patients participating in the
abatacept studies had similar baseline disease profiles
overall, though some studies included a high percentage
of rheumatoid factor positive patients [8-10,15], while
Table 5. Efficacy of golimumab
ACR 20 Response DAS28 Remission
Author Design Type Golimumab, % Control, % Golimumab Control Golimumab, % Control, % Comments
Emery et al. [21] R, DB, MTX naïve 61.60 49.40 CRP, 38.1 CRP, 28.1
placebo-
controlled
Kay et al. [22] R, DB, MTX failure 61 37 CRP, - 2.1 CRP, - 1 CRP, 26.3 CRP, 5.7
placebo-
controlled,
dose-ranging
Keystone et al. [23] R, DB, MTX failure 59.60 27.80 21.30 6
placebo-
controlled
Smolen et al. [24] R, DB, TNF-α 39 17 - 1.4 - 0.4 13 3
placebo- failure
controlled
ACR20, 20% response on the American College of Rheumatology criteria; DAS 28, 28 joint disease activity score; R, random; DB, double-blind; MTX, methotrexate;
CRP, C-reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; TNF, tumor necrosis factor.
Patients in the 50 mg
golimumab + MTX group and
the 100 mg golimumab +
MTX group had a median
improvement in CRP level
from baseline of 57.6%,
compared to 42.9% for those
in the placebo + MTX group.
Patients in the 50 mg
golimumab + MTX group and
the 100 mg golimumab +
MTX group had a median
improvement in HAQ-DI from
baseline of 45.9%, compared
to 37% for those in the
placebo + MTX group
At wk 2, median CRP levels
fell to normal or below normal
levels for all golimumab
groups, except for the group
receiving 50 mg golimumab
every 4 wk
Patients in the 50 mg
golimumab + MTX group and
the 100 mg golimumab +
MTX group experienced a
significantly greater reduction
in median HAQ-DI score
(- 0.44) by wk 24 compared
to the placebo + MTX group
(- 0.13)
At wk 24, approximately 52%
of patients on golimumab
experienced a clinically
significant reduction in HAQ-
DI, compared to just 34% of
patients on placebo8 The Korean Journal of Internal Medicine Vol. 25, No. 1, March 2010
Table 6. Efficacy of tocilizumab
ACR 20 Response DAS28 Remission
Author Design Type Tocilizumab, % Control, % Tocilizumab Control Tocilizumab, % Control, % Comments
Jones et al. [25] R, DB, MTX naïve 69.90 52.50 - 3.31 - 2.05 33.60 12.10
placebo-
controlled
Maini et al. [26] R, DB, MTX failure 74 41 - 3.57 - 1.35 34 8
placebo-
controlled
Nishimoto et al. [27] R, DB, MTX failure 80.30 25 - 3.1 - 0.7 43.10 1.60
placebo-
controlled
Smolen et al. [28] R, DB, MTX failure 59 26 - 3.4 - 1.5 27 0.80
placebo-
controlled
Nishimoto et al. [29] R, X-ray X-ray, 78
reader- inadequate 34
blinded, response to - 4.2
placebo- at least one - 1.1
controlled DMARD or 59
immunosuppressant 3
Genovese et al. [30] R, DB, DMARD 61 25 - 3.17 - 1.16 30 3
placebo- failure
controlled
Emery et al. [31] R, DB, TNFi 50 10.10 30.10 1.60
placebo- failure
controlled
ACR20, 20% response on the American College of Rheumatology criteria; DAS 28, 28 joint disease activity score; R, random; DB, double-blind; MTX, methotrexate;
CRP, C-reactive protein; VEGF, vascular endothelial growth factor; ESR, erythrocyte sedimentation rate; TSS, total modified Sharp score; DMARDs, disease-
modifying anti-rheumatic drugs; TNFi, tumor necrosis factor inhibitor.
In the tocilizumab group,
adjusted mean hemoglobin
levels increased from baseline
by 1.19 g/dL, compared to an
increase of 0.10 g/dL in the
MTX group.  Mean CRP levels
reached normal levels as early
as wk 2 in the tocilizumab
group
Mean ESR and CRP level
showed a significant decrease
over time in all patients treated
with tocilizumab except for the 2
mg/kg and 4 mg/kg tocilizumab
monotherapy groups
Mean serum VEGF levels
decreased markedly in the
tocilizumab group
Rapid, sustained
improvements in ESR, CRP,
and hemoglobin in the
treatment group
At wk 52, the mean TSS in
the tocilizumab group was
2.3, compared to 6.1 in the
conventional DMARDs group.
The mean erosion score at
this time was 0.9 for the
tocilizumab group and 3.2 for
the conventional DMARDs
group. At wk 52, patients in the
tocilizumab group also showed
less joint space narrowing than
those in the conventional
DMARDs, with respective
scores of 1.5 and 2.9  
Patients in the tocilizumab group
had decreased mean CRP,
decreased mean ESR, and
increased mean hemoglobin
levels
ESR and CRP levels dropped
markedly in the tocilizumab
groups by wk 2. Mean
hemoglobin levels in the
tocilizumab group increased
as early as wk 2Storage SS, et al. Three new biologics in the treatment of rheumatoid arthritis    9
Table 7. Adverse effects associated with  abatacepta [8,10,11,13,14,16,18,19]
Abataceptb Abatacept + DMARDsc Controld
Number of patients in studies 1,332  1,945  862 
Deaths 3 (0 - 0.4) 13 (0.2 - 1.7) 5 (0 - 1.6)
Discontinuation due to adverse effects 51 (3.5 - 3.9) 131 (1.9 - 17.1) 33 (0.9 - 9.2)
Discontinuation due to serious adverse effects 24 (0 - 2.7) 71 (1.2 - 11.1) 8 (0 - 1.5)
Adverse effects 1,046 (64.3 - 79.5) 1,590 (15 - 98.6) 621 (16 - 84)
Serious adverse effects 137 (2.6 - 10.5) 381 (3.2 - 46) 77 (1.7 - 11.9)
Infusion reaction, hr
Acute (≤ 1) 71 (3.6 - 5.5) 62 (5.1 - 8.8) 30 (2 - 10)
Peri-infusional (≤ 24) 2 (0 - 7.1) 106 (0 - 24.5) 40 (0 - 16.9)
Infectionse 266 (17 - 25.6) 512 (1.9 - 53.3) 240 (1.8 - 48.8)
Serious infectionsf 6 (0 - 2.3) 114 (1.3 - 12.7) 26 (0.9 - 16)
Cellulitis N/A 4 (0 - 0.7) 2 (0 - 0.5)
Abscess 2 (0 - 0.8) 8 (0 - 2) 8 (0.5 - 2)
Pneumonia 9 (0.6 - 1.1) 12 (0.4 - 1.4) 9 (0 - 1.4)
Tuberculosis 0 1 (0 - 0.2) 1 (0 - 0.5)
Sepsis 1 (0 - 0.4) 1 (0 - 0.2) 2 (0 - 0.8)
Otherg 0 3 (0 - 0.8) 1 (0 - 0.9)
Malignancy 16 (1.4 - 3.6) 38 (0.4 - 4.9) 6 (0 - 2.5)
Basal Cell CA 3 (0.2 - 3.6) 15 (0.6 - 2.1) 1 (0 - 0.9)
Squamous Cell CA N/A 3 (0.3 - 0.3) 1 (0 - 0.1)
Melanoma N/A N/A 1 (0 - 0.8)
Bladder cancer N/A 2 (0.3 - 0.4) 0
Lung cancerh 1 (0 - 0.1) 9 (0.3 - 1) N/A
Breast cancer 2 (0 - 0.2) 1 (0 - 0.3) N/A
Lymphoma N/A 3 (0.2 - 0.3) 0
Otheri 1(0 - 0.1) 5 (0.4 - 0.5) 2 (0 - 0.8)
Gastrointestinal
Nausea, vomiting, diarrhea, dyspepsia, 32 (0 - 12.4) 348 (1.3 - 35) 116 (0.4 - 28)
epigastric pain
Hemorrhage, diverticulitis 1 (0 - 0.4) 5 (0.4 - 1) 0
Central nervous system
Headache, dizziness 32 (0 - 12.4) 220 (1.3 - 26.8) 68 (0.9 - 19.1)
Cerebral vascular accident N/A 6 (0 - 1.4) 4 (0 - 1.8)
Pulmonary (non-infectious)
Dyspnea 1 (0 - 3.6) 4 (0 - 1.4) 0
Cough N/A 118 (6.7 - 22.3) 28 (5.9 - 12.6)
Cardiovascularj 4 (0.3 - 0.4) 45 (0.4 - 5.5) 6 (0 - 1.4)
Thromboembolic (pulmonary embolism, DVT) N/A 8 (0 - 2.7) N/A
Autoimmunek 22 (0.9 - 1.2) 34 (0.6 - 5.1) 6 (0.9 - 2)
Psoriasis 4 (0 - 0.4) 13 (1.1 - 2.1) 0
Abortion N/A 2 (0 - 0.8) N/A
Musculoskeletall 13 (0 - 5) 92 (1.7 - 7.2) 29 (4.6 - 5.5)
Auto antibodiesm 3 (0 - 1.3) 8 (0.9 - 1.4) 0
DMARD, disease-modifying anti-rheumatic drug; N/A, not available; CA, carcinoma; DVT, deep vein thrombosis; CVS, cardiovascular
syndrome; CHF, congestive heart failure; SLE, systemic lupus erythematosus.
aExcept where indicated otherwise, values are total number of patients and range of percent of patients.
bDosage of abatacept administered ranged from 2 to 10 mg/kg. Some patients were taking background non-steroidal anti-inflammatory
drugs and corticosteroids.others included a fairly high number of patients taking
concomitant corticosteroids [11,12,14,17].  Patients in
some abatacept studies also presented with fairly high
baseline DAS28 scores [8,13,14,18-20]. At least two of the
four golimumab studies included a fairly high percentage
of patients using corticosteroids [21,23], and three of the
four studies included patients with moderately high
baseline DAS28 scores [21,22,24]. Similarly, almost all of
the tocilizumab studies contained patients with high
baseline DAS28 scores [25,26,28-31]. Most studies reported
ACR20, 50, and 70 response rates as well as DAS28 response
and remission rates, and safety data were generally
adequately described.
Efficacy: abatacept (Table 4)
Methotrexate (MTX) naïve
One of the 13 abatacept studies examined the efficacy of
abatacept in MTX-naïve patients with early RA and poor
prognostic factors [8]. In that study, Westhovens et al. [8]
randomized participants 1 : 1 to receive either ~10 mg/kg
abatacept plus MTX or a placebo plus MTX. In the
abatacept group, 57.4% of patients achieved an ACR50 by
the end of the study, compared to 42.3% in the placebo
group. There was also a greater reduction in DAS28 in the
abatacept group (- 3.22 vs. - 2.49), and 41.4% of patients
in the abatacept group reached DAS-defined remission by
the end of the study, compared to just 23.3% in the
placebo group. Of note, there was significantly less radi-
ographic progression at 1 year in the abatacept plus MTX
group (mean change in TS = 0.63), as compared to the
placebo group (mean change in TS = 1.06).
MTX failure
Abatacept also shows promising efficacy in patients who
have responded inadequately to MTX. Of the 13 abatacept
studies examined, eight patients with active RA were
enrolled despite MTX therapy [9-16]. Across studies, a
significantly greater proportion of study participants in
the abatacept groups achieved an ACR20 than did those
in the placebo groups (Table 4) [9-11,14]. This ACR20
response appears to be maintained over time, as both a 2-
year and a 5-year open-label extension study reported that
over 80% of patients in the abatacept group achieved an
ACR20 by the end of the study [13,15]. According to a
2002 study by Moreland et al. [17], patients who failed
at least one classic DMARD (including MTX, gold,
sufasalazine, chloroquine, D-penicillamine, azathioprine,
leflunomide, or cyclosporine) or etanercept could also
benefit from abatacept, as 53% of patients in the abatacept
group achieved an ACR20, compared to 31% in the placebo
group. Inadequate MTX responders receiving abatacept
also appear to achieve DAS-defined remission at greater
rates than do those not receiving abatacept. In the 2005
and 2006 studies conducted by Kremer et al. [10,11],
34.8% (2005) and 23.8% (2006) of patients in the abatacept
groups achieved remission, compared to just 10.1%
(2005) and 1.9% (2006) in the placebo groups. Similarly,
Emery et al. [16] reported that remission rates in the
abatacept group were greater than in the placebo group at
all times during their study [16]. Of note, Schiff et al. [14]
determined that, in inadequate responders to MTX, a
greater proportion of patients receiving abatacept (18.7%)
reached remission than did patients receiving infliximab
(12.2%). As illustrated in Table 4, studies have shown
that inadequate responders to MTX receiving abatacept
rather than placebo also experience clinically meaningful
improvements in both summary scores and all eight SF-
36 subscales [9], statistically significant slowing of joint
structural damage [11,12], meaningful Health Assessment
Questionnaire-Disability Index (HAQ-DI) responses for
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cDMARDs, including methotrexate and sulfasalazine, azathioprine, penicillamine, gold, hydroxychloroquine, chloroquine, leflunomide,
anakinra. 
dControl groups included placebo groups and DMARDs.
eInfections were nasopharyngitis, influenza, urinary tract infection, upper respiratory tract infection, sinusitis, bronchitis.
f Serious infections were infections requiring intravenous antibiotics, hospitalizations, death.
gOther serious infections included bursitis, osteomyelitis, pseudomonas lung infection, postoperative wound infection, bacterial arthritis,
bronchopulmonary aspergilliosis, acute pyelonephritis.
hSmall cell CA, squamous cell CA, adeno CA, metastatic lung CA, and malignant lung neoplasms.
i Other malignancies included pancreatic cancer, uterine cancer, endometrial cancer, ovarian CA, myelodysplastic syndrome.
j CVS events include myocardial infarction, CHF, angina, hypertension, and cardiac arrest.
kOther autoimmune diseases like vasculitis of any type, SLE, sjorgrens, sicca syndrome, atrophic gastritis, erythema nodosum,
thyroiditis, multiple sclerosis but not including posriasis.
l Musculoskeletal disorders include back pain, rheumatoid arthritis worsening, arthralgias, connective tissue disorders.
mAuto antibodies to the whole molecule or the CTLA-4T portion of the drug.Storage SS, et al. Three new biologics in the treatment of rheumatoid arthritis    11
Table 8. Adverse effects associated with golimumaba [21-24]
Golimumabb Golimumab + DMARD’sc Controld
Number of patients in studies 291 891 666
Deaths 0 2 (0.3 - 0.8) 0
Discontinuation due to adverse effects 28 (0 - 8.8) 12 (1.3 - 7.3) 7 (3.1 - 5.9)
Discontinuation due to serious adverse effects N/A N/A N/A
Adverse effects 196 (66.4 - 68.2) 692 (73.7 - 86.1) 422 (52 - 85.3)
Serious adverse effects 10 (3.2 - 3.7) 59 (6 - 8.8) 50 (5.9 - 10)
Infusion reactions, hr  N/A N/A N/A
Acute (≤ 1)
Peri-infusional (≤ 24)
Infectionse 92 (27.6 - 35) 291 (26.3 - 37.6) 171 (21.7 - 38.2)
Serious infectionsf 3 (0.7 - 1.3) 22 (2 - 3) 16 (1.9 - 3)
Cellulitis 0 0 3 (0.6 - 1)
Abscess 0 0 1 (0 - 0.03)
Sepsis 0 3 (0.7 - 1.5) 2 (0 - 0.6)
Tuberculosisg 0 1 (0 - 0.3) 0
Pneumonia 0 7 (0.6 - 2.2) 1 (0 - 1)
UTI  1 (0 - 0.7) 1 (0 - 0.3) 2 (0  - 0.06)
Otherh 0 6 (0.7 - 1.3) 6 (0.6 - 2.9)
Malignancy 1 (0 - 0.7) 10 (0.6 - 2.9) 4 (0.3 - 1.3)
Sq cell ca Skin 0 2 (0.3 - 0.8) 1 (0 - 0.6)
Basal CA 1 (0 - 0.7) 3 (0.8 - 1.5) 0
Lung CA N/A 1 (0 - 0.7) 0
Lymphoma 0 2 (0 - 0.3) 0
Breast cancer 0 1 (0 - 0.3) 2 (0.3 - 0.6)
Otheri N/A N/A 1 (0 - 1)
Gastrointestinal (all)
Nausea, vomiting, diarrhea, 24 (0 - 15.2) 130 (0.8 - 28) 25 (2.9 - 16.8)
dyspepsia, epigastric pain, oral ulcers,
peptic ulcers, abdominal pain.
Hemorrhage, polyps, colitis 0 1 (0 - 0.8) 0
Central nervous system
Headache, dizziness, fatigue, insomnia 24 (0 - 15.2) 58 (14.8 - 15.3) 25 (11.2 - 20.6)
Cerebral vascular accident N/A N/A N/A
Pulmonary (non-infectious) N/A 1 (0 - 0.7) N/A
Dyspnea
Cough (non-infectious)
Cardiovascularj 4 (0 - 2.5) 17 (1.5 - 5) 19 (1 - 4.4)
Vascular N/A N/A N/A
Musculoskeletalk N/A 51 (11.1 - 12.4) 31 (15.4 - 20.6)
Skinl 6 (0 - 3.8) 13 (0 - 4) 7 (0 - 0.4)
Hematological 2 (0 - 1.3) 1 (0 - 0.7) 0
Autoimmune disordersm 27 (14.3 - 14.9) 94 (7 - 29.3) 49 (3.8 - 17.4)
LFT abnn 19 (0 - 12.1) 114 (8 - 32.4) 30 (2.9 - 18.1)
Injection site disordero 21 (3 - 10.8) 82 (6.5 - 18.2) 23 (3.1 - 11.8)
Anti-golimumab auto antibodies  16 (1.5 - 13.5) 24 (0.9 - 6.5) 0
DMARD, disease-modifying anti-rheumatic drug; N/A, not available; UTI, urinary tract infection; CA, carcinoma; LFT, liver function test;
COX, cyclooxygenase; ANA, anti-nuclear antibody; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
aExcept where indicated otherwise, values are total number of patients and range of percent of patients (range, %).
bDosage of golimumab administered ranged from 2 to 8 mg/kg. Some patients were taking background non-steroidal anti-inflammatory
drugs including COX2 inhibitors and corticosteroids.physical functioning [13], and meaningful mHAQ responses
for physical functioning [15]. 
TNF-αfailure
In a 2005 study conducted by Genovese et al. [18], the
investigators determined that patients who responded
inadequately to TNF-α inhibitors could benefit from
taking abatacept. In that study, 50.4% of patients in the
abatacept group and only 19.5% of patients in the placebo
group achieved an ACR20 by the end of the 6-month
study. Additionally, 10% of patients in the abatacept group
reached DAS-defined remission, whereas less than 1% of
patients in the placebo were able to reach this milestone.
Also at 6 months, 47.3% of patients in the abatacept group
and 23.3% of patients in the placebo group experienced
clinically meaningful improvement in physical function as
defined by a reduction of at least 0.3 from the HAQ-DI
baseline. According to Schiff et al. [19], a slightly greater
proportion of patients achieve remission (13.7%) when
they switch directly from inadequate anti-TNF-α therapy
to abatacept, as compared to patients who switch to
abatacept following a washout period of at least 2 months
(12%). Other measures of efficacy also support the use
of abatacept in patients who have failed prior TNF-α
inhibitor therapy. For example, Westhovens et al. [20]
observed that treatment group patients saw significant
improvements in quality of life as assessed by the HAQ
and fatigue indices, as well as on the SF-36 (short form
36) physical and mental summary scores and on seven of
the eight SF-36 scales.
Efficacy: golimumab (Table 5)
MTX naïve
Of the four golimumab studies examined, one examined
the efficacy of golimumab in MTX naïve patients with RA
[21]. In this year-long study, Emery et al. [21] determined
that 61.6% of patients in the golimumab group and 49.4%
of patients in the placebo group obtained an ACR20 by the
end of the investigation. Also, 38.1% of patients receiving
golimumab achieved a DAS-defined remission using
C-reactive protein (CRP) level, compared to 28.1% of
patients in the placebo group. Patients who received
golimumab also saw a median improvement in HAQ-DI
from a baseline of 45.9%, while patients receiving placebo
saw an improvement of 37%.
MTX failure
Golimumab also appears to be efficacious in patients
who have failed to respond adequately to MTX treatment.
Kay et al. [22] found that 61% of patients receiving
golimumab and 37% of patients receiving a placebo
achieved an ACR20 by the end of the 68-week study.
Furthermore, DAS-defined remission rates were greater
in those receiving golimumab (Table 5). The results of a
2009 study also support the efficacy of golimumab
therapy in patients failing MTX treatment [23]. In this
study, Keystone et al. [23] reported that 59.6% of patients
in the golimumab group obtained an ACR20 during the
study, while only 27.8% of patients in the placebo group
did the same. More patients in the golimumab group
(21.3%) achieved DAS-defined remission than did those in
the placebo group (6%), which are similar to the results
offered by Kay et al. [22]. 
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c DMARDs, including methotrexate and sulfasalazine, azathioprine, penicillamine, gold, hydroxychloroquine, chloroquine, leflunomide,
anakinra, salazosulfapyridine, and bucillamine, mizoribine.
d Control groups included placebo groups and DMARDs.
e Infections were nasopharyngitis, upper respiratory tract infection, cough, sinusitis, and bacterial infections not otherwise specified.
f Serious infections were infections requiring intravenous antibiotics, hospitalizations, or death.
g Patients with tuberculosis at baseline were not included.
h Other serious infections included, osteomyelitis, bacterial arthritis, infective arthritis, lower respiratory tract infection, bronchitis,
urosepsis, infected cystic lymphangioma, gasterointeritis, pelvic inflammatory disease, and sinusitis.
i Other malignancies included pancreatic cancer.
j Cardiovascular events included myocardial infarction, angina, congestive heart failure, hypertension, and cardiac arrest.
k Musculosketal disorders included back pain, worsening rheumatoid arthritis, arthralgia, and a fractured coccyx.
l Skin manifestations included rash.
mIncludes ANA positivity, anti double strained DNA positivity. None of the patients developed systemic lupus erythematosus or erthyma.
n Liver function test abnormalities including elevations in ALT, AST and bilirubin levels. Most were unconjugated bilirubinemias (four
people were on Tb prophylaxis i.e. isoniazid).
o Injection site reactions included erythema, bruising, warmth, pruritus, pain, induration, burning, hemorrhaging, stinging, urticaria, and
swelling.Storage SS, et al. Three new biologics in the treatment of rheumatoid arthritis    13
Table 9. Adverse effects associated with tocilizumaba [25-31]
Tocilizumabb Tocilizumab + DMARDsc Controld
Number of patients in studies 665 1,709 1,173
Deaths 3 (0 - 1) 2 (0 - 0.3) 3 (0.4 - 0.5)
Discontinuation due to adverse effects 11 (0 - 3.8) 51 (3.9 - 5.9) 31 (1.9 - 5.3)
Discontinuation due to serious adverse effects 14 (0 - 8.8) 29 (3.8 - 9.9) 6 (1 - 8.1)
Adverse effects 468 (26.4 - 91.8) 1,202 (23.1 - 85.5) 905 (18.3 - 82)
Serious adverse effects 51 (3.8 - 18) 78 (2.9 - 6.8) 78 (2.8 - 13)
Infusion reactions, hr  22 (3.7 - 11.5) N/A 5 (0 - 1.8)
Acute (≤ 1)
Peri-infusional (≤ 24) 16 (0 - 5.6) N/A N/A
Infectionse 129 (14.2 - 42.6) 514 (1.4 - 47.9) 323 (11.2 - 41.3)
Serious infectionsf 20 (1.4 - 7.6) 45 (1.9 - 3.7) 25 (0.7 - 5.5)
Cellulitis 2 (0 - 1.3) 8 (0.3 - 0.6) 1 (0 - 0.6)
Abscess 2 (0 - 0.6) 1 (0 - 0.2) 3 (0 - 1.5)
Sepsis 0 2 (0 - 1.3) 2 (0.4 - 0.7)
Tuberculosisg 0 1 (0 - 0.1) 0
Pneumonia 5 (0.7 - 1.9) 7 (0.3 - 0.7) 6 (0.4 - 1.6)
Otherg 6 (0.6 - 2.5) 6 (0.6 - 0.7) 6 (0.6 - 3.4)
Malignancyh 4 (0.3 - 1.9) 0 5 (1 - 1.1)
Colon CA 1 (0 - 0.6) N/A N/A
Breast cancer 2 (0 - 1.3) N/A N/A
Otheri 0 0 2 (0.4 - 0.5)
Gastrointestinal (all) 116 (19.1 - 29.9) 378 (20.8 - 34.6) 245 (13.7 - 31.3)
Nausea, vomiting, diarrhea, 37 (6.6 - 11.5) 56 (1.1 - 11.2) 64 (0.2 - 17.2)
dyspepsia, epigastric pain, oral ulcers,
peptic ulcers, abdominal pain
Hemorrhage, polyps, colitis 2 (0.3 - 1.6) 6 (0.5 - 1.2) 4 (0.5 - 1.6)
Central nervous system 37 (0 - 128) 213 (11.6 - 18.9) 107 (6.3 - 16.9)
Headache, dizziness, fatigue, insomnia 63 (6.6 - 7.3) 77 (6 - 6.9) 33 (2.5 - 4)
Cerebral vascular accident N/A 8 (0.5 - 0.7) 3 (0 - 0.5)
Pulmonary (non-infectious) 0 170 (7.1 - 13.3) 72 (5 - 13.1)
Dyspnea 0 6 (0 - 1.4) 0
Cough 0 10 (0 - 2.4) 3 (0 - 1)
Cardiovascular j 2 (0 - 0.7) 34 (0.4 - 5.6) 16 (0.2 - 4)
Vascular N/A 139 (6.7 - 9.4) 52 (4.6 - 5.1)
Musculoskeletalk 36 (0.6 - 11.5) 221 (1.2 - 1.8) 174 (2 - 21.3)
Skinl 90 (6.6 - 2.8) 285 (15.3 - 26) 116 (3.1 - 14.4)
Hematological (non-malignant) N/A 15 (0.5 - 3.8) 4 (0 - 2.5)
Ophthalmic 15 (0 - 5.2) 22 (0 - 6.5) 12 (1.9 - 3.2)
Psychiatric 20 (0 - 6.9) 29 (0 - 8.6) 17 (3.8 - 3.9)
Renal and urinary disorders N/A 3 (0 - 04) N/A
Lipid abnormalitym 226 (16.3 - 83.6) 588 (14 - 55.2) 74 (0.4 - 14.4)
HDL 38 (0 - 24) 51 (0 - 15) 6 (0 - 3.8)
LFT abnormalityn 345 (9.8 - 100) 894 (2.3 - 100) 356 (0.6 - 59.8)
Neutropenia 130 (25.1 - 31.3) 425 (24.2 - 29) 51 (0.6 - 10.2)
Anti-tocilizumab auto antibodies  29 (2.5 - 15.7) N/A N/A
DMARD, disease-modifying anti-rheumatic drug; N/A, not available; CA, carcinoma; HDL, high density lipoprotein; LFT, liver function
test; COX, cyclooxygenase; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
a Except where indicated otherwise, values are total number of patients and ranges of the percent of patients (range, %).
b Dosages of tocilizumab ranged from 2 to 8 mg/kg. Some patients were taking background non-steroidal anti-inflammatory drugs
including COX2 inhibitors and corticosteroids.TNF-αfailure
Golimumab also seems to be of clinical use in patients
who have failed TNF-α inhibitor treatment. In a 2009
study by Smolen et al. [24], of the patients failing TNF-α
inhibitor therapy, 39% of those in the golimumab group
and 17% of those in the placebo group reached an ACR20
by the end of the 24-week study. Thirteen percent of
patients in the golimumab group reached DAS-defined
remission by the end of the study, which was significantly
more than the 3% of patients in the placebo group who
achieved remission. At week 24, approximately 52% of
patients on golimumab experienced a clinically significant
reduction in HAQ-DI, compared to just 34% of patients
on placebo.
Efficacy: tocilizumab (Table 6)
MTX naïve
In their 2009 study, Jones et al. [25] examined the
efficacy of tocilizumab in MTX naïve patients with RA.
Nearly 70% of patients in the tocilizumab group were able
to obtain an ACR20 by the end of the 24-week study,
compared to 52.5% of patients in the control group.
Additionally, 33.6% of patients in the tocilizumab group
and only 12.2% of patients in the control group achieved
DAS-defined remission during the study.
MTX failure
Tocilizumab also appears to show promising efficacy in
patients with RA who have responded inadequately to
MTX. Across studies, a greater proportion of inadequate
responders to MTX treated with tocilizumab achieve an
ACR20 than do inadequate responders to MTX in control
groups (Table 6) [26-28]. Patients failing MTX treatment
who receive tocilizumab also demonstrate rapid, sustained
improvements in erythrocyte sedimentation rate (ESR),
CRP, and hemoglobin than do patients assigned to control
groups [26,28]. Nishimoto et al. [29] and Genovese et al.
[30] suggest that this efficacy holds for patients failing
with DMARDs other than MTX. For example, Nishimoto
et al. [29] determined that 78% and 59% of patients
receiving tocilizumab achieved an ACR20 and remission,
respectively, while 34% in the control group achieved
ACR20 and 3% achieved remission. That study also found
that the mean erosion score at week 52 was 0.9 for the
tocilizumab group and 3.2 for the control group, and that
joint space narrowing was reduced in the tocilizumab
group. Genovese et al. [30] reported similar ACR20 and
remission rates, and suggested that patients in the
tocilizumab group had decreased mean CRP, decreased
mean ESR, and increased mean hemoglobin levels (Table 6).
TNF-αfailure
One study investigated the efficacy of tocilizumab in
patients who failed TNF-α inhibitor treatment. In a 2009
study, Emery et al. [31] reported that 50% of patients
receiving tocilizumab and 10.1% of patients in the control
group obtained ACR20. Also, 30.1% in the tocilizumab
group and only 1.6% control group patients achieved
remission by the end of the study. As with the MTX failure
studies, patients who fail TNF-α inhibitor treatment and
receive tocilizumab show significant reductions in ESR
and CRP levels and increased hemoglobin levels [31].  
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c DMARDs including methotrexate and sulfasalazine, azathioprine, penicillamine, gold, hydroxychloroquine, chloroquine, leflunomide,
anakinra, salazosulfapyridine, bucillamine, and mizoribine.
d Control groups included placebo groups and DMARDs.
e Infections were nasopharyngitis, somatitis, upper respiratory tract infection, and bacterial infections not otherwise specified.
f Serious infections were infections requiring intravenous antibiotics, hospitalizations, or death.
g Other serious infections included osteomyelitis, bacterial arthritis, infective arthritis, lower respiratory tract infection, pleural effusion,
viral herpes zoster, herpes simplex, gastroenteritis, staphylococcal polyarthritis, urosepsis, empyema, and unidentified infections.
h Malignancies included the below mentioned malignancies and others not otherwise specified.
i Other malignancies included pancreatic cancer, uterine cancer, endometrial cancer, ovarian carcinoma, myelodysplastic syndrome,
squamous cell cancer of the skin, and lung cancer.
j Cardiovascular events included myocardial infarction, angina, congestive heart failure, hypertension, and cardiac arrest.
k Musculosketal disorders included back pain, rheumatoid arthritis worsening, arthralgias, connective tissue disorders, and
compression fractures.
l Skin manifestations included rash, eczema, pruritus, and paronychia.
mLiver function test abnormalities included elevations in ALT, AST and bilirubin levels. Most were unconjugated bilirubinemias, and a
simultaneous rise in ALT and bilirubin levels were not frequently seen.
n Increase in low density lipoprotein, total cholesterol, and triglycerides (values may be combined or an individual number depending
upon the study data available).Safety: abatacept (Table 7)
While abatacept, golimumab, and tocilizumab are
generally regarded as safe and well tolerated, the inherent
immunosuppressive nature of these drugs requires
caution in their use. We examined nine studies evaluating
abatacept as either a monotherapy or in combination with
DMARDs, and the results regarding safety are shown in
Table 7 [8,10,11,13-16,18,19]. Given that these studies
varied in design and methods for assessing safety
outcomes, the results presented in Table 7 should be
interpreted with caution. As expected, the combination of
abatacept plus another DMARD was generally associated
with more adverse events of all types, although the overlap
of ranges indicates that the differences are not likely to be
statistically significant. For example, patients in the
abatacept plus DMARD category experienced more
serious adverse effects (3.2 to 46%) than those in the control
group (1.7 to 11.9%). Tuberculosis was observed in both the
abatacept plus DMARDs group and the control group (one
case in each group). Within the abatacept plus DMARDs
group, both hemorrhage (0.4 to 1%) and cardiovascular
complications (0.4 to 5.5%) occurred, but not statistically
more often than in the control group (0.0% and 0.0 to 1.4%,
respectively).    
Table 7 delineates a particularly interesting set of
observations regarding malignancies. Malignancy rates
in both the abatacept only group (1.4 to 3.6%) and the
abatacept plus DMARDs group (0.4 to 4.9%) overlapped
considerably with malignancy rates in the control group
(0.0 to 2.5%), implying little to no difference in malignancy
risk among these three groups. However, an evaluation
of the specific malignancy types suggested the possibility
that some tumors were more common when using abatacept.
These data approach statistical significance and raise the
possibility that more data should be gathered for these
cancers.  Rates of basal cell carcinoma in the abatacept only
and abatacept plus DMARDs groups (0.2 to 3.6%) occurred
at a greater frequency than in the control group (0.0 to 0.9%).
Also, three cases of squamous cell carcinoma were observed
in the abatacept plus DMARDs group, compared to just
one case in the control group. Additionally, three patients
in the abatacept plus DMARDs group developed lymphoma,
whereas no patients in the control group experienced this
complication. Finally, three patients within the abatacept
only and abatacept plus DMARDs groups developed
breast cancer, and 10 patients developed lung cancer.
Safety: golimumab (Table 8)
We examined four studies evaluating golimumab as
either a monotherapy or in combination with DMARDs.
The safety data are combined and displayed in Table 8
[21-24]. Again, we limit our discussion to selected
observations from Table 8, and do not imply that any of
these observations are of statistical significance. Rather,
they are presented as clinical considerations to consider
when using this biologic. Patients receiving golimumab
alone or golimumab plus DMARDs experienced more
adverse skin events (0.0 to 4.0%) than the control group
(0.0 to 0.4%). Similarly, patients receiving golimumab plus
DMARDs had more pneumonia (0.6 to 2.2 vs. 0.0 to 1.0% for
control), malignancy (0.6 to 2.9 vs. 0.3 to 1.3% for control),
and basal cell carcinoma (0.8 to 1.5 vs. 0.0% for control).
Safety: tocilizumab (Table 9)
To evaluate the safety of tocilizumab, we examined
seven studies investigating the biologic alone or in
combination with DMARDs [25-31]. The results of these
studies are presented in Table 9. Our discussion of Table 9
is limited to selected clinical observations and does not
imply statistical significance. Patients using tocilizumab
monotherapy generally experienced more adverse effects
(26.4 to 91.8%) and serious adverse effects (3.8 to 18%)
than those in the control group (18.3 to 82% and 2.8 to 13%,
respectively). Perhaps most interesting in Table 9 is the
apparent increase in high density cholesterol (HDL), total
cholesterol, and liver function test abnormalities, and
neutropenias in patients receiving tocilizumab alone or
tocilizumab plus DMARDs than control group patients.
Between 0.0 and 24% of patients in the tocilizumab and
tocilizumab plus DMARDs group saw HDL increases,
compared to just 0.0 to 3.8% of patients in the control group.
Similarly, in the tocilizumab and tocilizumab plus DMARDs
groups, a greater number of patients experienced lipid
abnormalities (14 to 83.6%) and liver function test
abnormalities (2.3 to 100%) than did those in the control
group (0.4 to 14.4% and 0.6 to 59.8%, respectively). While
only 0.6 to 10.2% of patients in the control group exhibited
neutropenia, between 24.2 and 31.3% of patients in the
tocilizumab and tocilizumab plus DMARDs groups
showed this side effect. Of note, these ranges did not
overlap. Taken together, these observations suggest that
physicians should consider HDL increases, lipid and liver
function test abnormalities, and neutropenia when using
tocilizumab.
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Abatacept, golimumab, and tocilizumab represent three
new drugs targeting specific biological molecules to treat
RA. Abatacept demonstrates acceptable safety and
tolerability, and clinically meaningful efficacy in patients
who are MTX naïve or who have had an inadequate
response to prior conventional DMARDs or TNF-αinhibitor
therapy. Golimumab effectively reduces the signs and
symptoms of RA and is generally well tolerated in patients
who are MTX naïve or who have failed conventional
DMARD or TNF-αinhibitor treatment. Similarly, tocilizumab
has been shown to be effective for improving the signs and
symptoms of RA and has a safety profile similar to abatacept
and golimumab, although it causes reversible increases in
triglycerides, LDL-cholesterol, and liver enzymes. Despite
these encouraging results, the place for each of these
drugs in the RA armamentarium is not fully understood
given the lack of head-to-head studies and long-term
extension data.
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